Roche Holding AG

Equities

ROG

CH0012032048

Market Closed - Swiss Exchange Other stock markets 11:31:37 2025-06-19 am EDT			5-day change	1st Jan Change
260.00 ^CHF	+0.35%		-4.62%	+1.76%

Jun. 19	Obesity: preserving muscle, the new challenge
Jun. 19	Swiss trade surplus at CHF 3.831 bln in May	RE

Roche Holding AG, Q1 2025 Sales/ Trading Statement Call, Apr 24, 2025

Published on 04/24/2025 at 08:00

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, welcome to Roche's First Quarter Sales Webinar 2025. My name is [ Henrik ], and I'm the technical operator for today's call.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Roche Holding AG

Obesity: preserving muscle, the new challenge	Jun. 19
Swiss trade surplus at CHF 3.831 bln in May	Jun. 19	RE
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	Jun. 18	RE
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise	Jun. 18	MT
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies	Jun. 18	CI
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	Jun. 18	RE
ROCHE HOLDINGS AG : Sell rating from Deutsche Bank	Jun. 17	ZD
Swiss stocks - Factors to watch on June 17	Jun. 17	RE
Sarepta shares crash as second patient dies after receiving its gene therapy	Jun. 16	RE
ROCHE HOLDINGS AG : Gets a Buy rating from UBS	Jun. 16	ZD
Swiss Stocks Kick Off New Trading Week Downbeat Amid Gloomy Economic Forecasts	Jun. 16	MT
Analyst recommendations: Meta, Eli Lilly, RTX Corp, Airbus, Roche…	Jun. 16
AbbVie says blood cancer drug fails late-stage trial	Jun. 16	RE
Upcoming Fed Meeting Eyed as US Equity Futures Rise Pre-Bell	Jun. 16	MT
North American Morning Briefing : Stock Futures Rise As Israel-Iran Conflict Enters Fourth Day	Jun. 16	DJ
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development	Jun. 16	MT
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures	Jun. 16	DJ
Roche: moving towards phase 3 in Parkinson's disease	Jun. 16	CF
Roche to Advance Prasinezumab Into Phase 3 Trial for Early-Stage Parkinson's Disease	Jun. 16	DJ
Roche to Proceed with Phase Three Development of Investigational Drug for Parkinson's Disease	Jun. 16	MT
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease	Jun. 16	CI
Roche To Advance Prasinezumab Into Phase III Development For Early-Stage Parkinson's Disease	Jun. 16	RE
Swiss stocks - Factors to watch on June 16	Jun. 16	RE
Sarepta reports second case of liver failure death after its gene therapy treatment	Jun. 15	RE
Roche Updates Treatment Profile, Dosing Restrictions for Duchenne Muscular Dystrophy Treatment	Jun. 15	MT